



According to Philip Nuzzo, Vice President of OEM, Respironics Critical Care, “The addition of LoFlo Sidestream technology now provides customers with the most flexible CO₂ solution available. We are excited that ZOLL has chosen to include the LoFlo technology in their E Series defibrillator as a complement to their existing CAPNOSTAT[®] 5 mainstream solution. We look forward to working with ZOLL to extend our reach in the sidestream market space.”

About Respironics, Inc.

The LoFlo[™] Sidestream CO₂ Sensor joins the Respironics family of other OEM technologies, including the CAPNOSTAT[®] 5 Mainstream CO₂ Sensor, FloTrak[™] Respiratory Mechanics Module, and other respiratory monitoring products such as the NICO₂[®] Respiratory Profile Monitor and the Tidal Wave[®] Handheld CO₂ Capnograph, both available for private label applications. Respironics also provides comprehensive engineering, clinical and marketing support services to assist its OEM customers.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,700 associates worldwide. Further information can be found on the Company’s Web site: www.respironics.com.

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

#

“Respironics”, “CAPNOSTAT”, “NICO” and “Tidal Wave” are registered trademarks, and “LoFlo” and “FloTrak” are trademarks of Respironics, Inc. and its affiliates. “ZOLL” and “E Series” are trademarks of ZOLL Medical Corporation.
© 2006 Respironics, Inc. and its affiliates.

CORPORATE SERVICES
1010 Murry Ridge Lane ~ Murrysville, PA 15668
T 724-387-5200 F 724-387-5010